SCHEMBL4352087

SCHEMBL4352087

CS(=O)(=O)c1ccc(-c2ccc(OC3CN(Cc4ccc(F)c(Oc5ccccc5)c4)C3)cc2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.39
RORC P51449 1/20 0.36
PTPN1 P18031 1/20 0.36
SCN8A Q9UQD0 4/20 0.36
SCN1A P35498 3/20 0.36
KCNJ1 P48048 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CACNA1H O95180 1/20 0.35
GALR3 O60755 1/20 0.35
RAB9A P51151 1/20 0.35
PDE1B Q01064 1/20 0.35
S1PR5 Q9H228 1/20 0.35
SSTR5 P35346 1/20 0.34
ACACB O00763 1/20 0.34
S1PR1 P21453 1/20 0.34
SCN3A Q9NY46 1/20 0.34
EGFR P00533 2/20 0.34
ERBB2 P04626 2/20 0.34
CHEK2 O96017 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350062 0.88 PTPN1 (0.45) RORCPTPN1KCNJ1S1PR5ACACB
SCHEMBL4351876 0.87 FAAH (0.45) RORCPTPN1ACACB
SCHEMBL4345654 0.85 RORC (0.43) RORCPTPN1KCNJ1S1PR5ACACB
SCHEMBL14403658 0.85 KCNH2 (0.36) RORCKCNJ1CACNA1HRAB9AACACB
SCHEMBL4353675 0.84 RORC (0.44) RORCPTPN1SCN8ASCN1AS1PR5
SCHEMBL4348446 0.84 KCNJ1 (0.39) RORCPTPN1KCNJ1ACACB
SCHEMBL4362416 0.83 DPP4 (0.44) KCNJ1CACNA1H
SCHEMBL4346924 0.82 GRIN1 (0.43) RORCMEN1KMT2AS1PR5S1PR1
SCHEMBL4347016 0.82 NPC1 (0.48) MEN1KMT2ARAB9AS1PR5S1PR1
SCHEMBL4344611 0.81 PTPN1 (0.42) RORCPTPN1KCNJ1S1PR5S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP claimed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US claimed
EP-2010485-B1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2012-10-17 EP disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists PROSIDION LIMITED (GB) 2009-11-12 US disclosed
WO-2007116230-A1 AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS PROSIDION LTD (GB) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281076-A1 Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists GPR119, GPR39, GIPR DRD4 1110/4885RORC 728/4885PTPN1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.